Genitourinary Cancers

Primary chemoablation with UGN-102 elicited encouraging responses in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer and may consequently be an appropriate nonsurgical treatment intervention for patients.

Ziad Bakouny, MD, MSc, discusses the controversy behind the use of cytoreductive nephrectomy in metastatic renal cell carcinoma, factors to consider when selecting patients for this approach, and ongoing trials examining remaining questions in the field.

As part of the 2020 ASCO Direct Highlights™ webcast, Brian Rini, MD, discusses key developments in genitourinary cancers that were presented during the 2020 ASCO Virtual Scientific Program.

Only a small percentage of patients with kidney cancer who are considered to be particularly vulnerable to COVID-19 have actually been tested for infection.

Pembrolizumab plus axitinib continued to significantly improve efficacy over sunitinib in patients with previously untreated metastatic renal cell carcinoma, according to updated results from the phase 3 KEYNOTE-426 trial.

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Eric Jonasch, MD, on the favorable efficacy and tolerability of MK-6482 in patients with Von Hippel-Lindau disease–associated renal cell carcinoma.

The FDA has approved avelumab (Bavencio) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy.

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Félix Guerrero-Ramos, MD, PhD, FEBU, discusses the role of Bacillus Calmette-Guerin in the treatment of patients with non-muscle invasive bladder cancer.

Scott S. Tykodi, MD, PhD, discusses the efficacy of dual checkpoint blockade in renal cell carcinoma.

Investigators are using a novel clinical trial design to test multiple treatment strategies in an effort to define the standard of care in squamous cell carcinoma of the penis.

Sumanta K. Pal, MD, discusses the background of the COSMIC-021 trial in urothelial cancer.

Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer​.

In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.

Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.

Chung-Han Lee, MD, PhD, discusses the efficacy of combining immunotherapy with TKIs to treat patients with metastatic renal cell carcinoma.

Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma.

Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.

Rana R. McKay, MD, discusses the design and key findings of the OMNIVORE trial, as well as other ongoing adaptive trials in renal cell carcinoma.

Adding pembrolizumab to chemotherapy did not lead to a statistically significant improvement in overall survival or progression-free survival in patients with advanced or metastatic urothelial carcinoma, according to findings from the phase 3 KEYNOTE-361 trial.

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

Sumanta K. Pal, MD, discusses the clinical implications of the COSMIC-021 trial and highlights other exciting research efforts being made in genitourinary cancers.

John P. Sfakianos, MD, discusses the utility of adjuvant therapy in bladder cancer management.

Elizabeth R. Plimack, MD, MS, discusses the updated findings from the phase 3 KEYNOTE-426 study in patients with previously untreated, advanced renal cell carcinoma.

Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered.

The FDA has accepted a new drug application for tivozanib for the treatment of patients with relapsed/refractory renal cell carcinoma.

The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.

Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.